Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

FDA
News

Catalyst Biosciences Sponsored Study Titled ‘Screening Study to Identify Patients With Complement Factor I Deficiencies’ Posted To ClinicalTrials.Gov; Study Not Yet Recruiting

https://clinicaltrials.gov/ct2/show/NCT05072912

byBenzinga Newsdesk

October 11, 2021

1 minute read

https://clinicaltrials.gov/ct2/show/NCT05072912

Centogene Q2 Revenues €51.9M, Up 434% YoY; Commercial OVID-19 Testing Revenues €42.3M, Up From €2.1M YoY

By Bill Haddad

Today, 3:54 PM

Revenues of €51.9 million in Q2 2021, a 434% increase compared to €9.7 million in Q2 2020; Revenues from the Company’s Pharma and Diagnostics segments (“Core

CNTG

News

‘Paterson schools to go fully remote until January 18 as NJ COVID cases surge’ – ABC7 New York

By Benzinga Newsdesk

Today, 3:54 PM

https://abc7ny.com/nj-covid-omicron-new-jersey-in-gov-phil-murphy/11370028/

BOXL

Ipsen to Acquire Epizyme for $1.45/Share in Cash, Plus a Contingent Value Right of $1.00/Share

By Charles Gross

Today, 3:54 PM

Ipsen (Euronext: IPN; ADR: IPSEY) and Epizyme (Nasdaq: EPZM) today announced that they have entered into a definitive merger agreement under which Ipsen will acquire Epizyme.

EPZM

Lake Street Initiates Coverage On Electromed with Buy Rating, Announces Price Target of $20

By Benzinga Newsdesk

Today, 3:54 PM

Lake Street analyst Kyle Bauser initiates coverage on Electromed (AMEX:ELMD) with a Buy rating and announces Price Target of $20.

ELMD

Catalyst Biosciences Sponsored Study Titled ‘Screening Study to Identify Patients With Complement Factor I Deficiencies’ Posted To ClinicalTrials.Gov; Study Not Yet Recruiting

Related Posts

Centogene Q2 Revenues €51.9M, Up 434% YoY; Commercial OVID-19 Testing Revenues €42.3M, Up From €2.1M YoY

‘Paterson schools to go fully remote until January 18 as NJ COVID cases surge’ – ABC7 New York

Ipsen to Acquire Epizyme for $1.45/Share in Cash, Plus a Contingent Value Right of $1.00/Share

Lake Street Initiates Coverage On Electromed with Buy Rating, Announces Price Target of $20